EXINI Diagnostics AB

EXINI’s biomarker BSI for oral presentation at SNMMI

EXINI´s imaging biomarker BSI to be presented at ASCO

EXINI and Bone Scan Index (BSI) in two articles in important German Urology journal

EXINI: New upgrade agreement with FUJIFILM RI Pharma

EXINI and FUJIFILM RI Pharma in co-sponsored BSI-seminar in Tokyo

EXINI signs BSI-agreement with university hospital RWTH Aachen

EXINI appoints Henrik Perlmutter as Chairman of the Board

EXINI´s imaging biomarker BSI to be presented at important congress on prostate cancer

EXINI heart reaches 500 installations in Japan

EXINI enters collaboration with DexTech Medical

EXINI and FUJIFILM RI Pharma’s symposium on BSI attracted attention at important European Congress

EXINI to arrange Bone Scan Index (BSI) symposium at important annual European congress

EXINI: New BSI-results to be presented at cancer conference

EXINI’s heart-product fast growing on the Japanese market – hits 300 installed units

EXINI’s heart product hits 100 installations in Japan

EXINI: Bone Scan Index (BSI) as therapy-monitoring imaging biomarker, to be presented at the 2014 German Congress for Urology, DGU, in Düsseldorf

EXINI and FUJIFILM RI Pharma co-sponsors seminar on BSI and Imaging Biomarkers at the Sweden Life Science Summit in Tokyo

EXINI completes heart project for the Japanese market

EXINI: Benefits using BSI highlighted at the annual Japanese Urological Association’s meeting in Kobe, April 24-27, 2014

EXINI: Round table session focusing on imaging biomarkers at world congress

EXINI launching a new website about the imaging biomarker Bone Scan Index

EXINI: Success for BSI at large congress on urological cancer

EXINI: Bonenavi 2.0 is now officially released

EXINIs investment in imaging biomarkers attracted considerable interest at EANM (European Association of Nuclear Medicine)

EXINI signs new commercial agreement with pharmaceutical company

EXINI signs new agreement with FUJIFILM RI Pharma

EXINI and Active Biotech present mutual results at US cancer conference

EXINI and Active Biotech initiate collaboration, aiming to clinically evaluate the future of cancer treatment.

EXINI: Focus on opportunities with BSI at the ‘Bone Scan Index meeting’ in Malmö

Breakthrough for EXINI, FDA approval for EXINI bone™.